SUPPLEMENTARY MATERIAL

LIST OF STUDIES INCLUDED IN THE SYSTEMATIC REVIEW

1. Aapro M, Leonard RC, Barnadas A, et al: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. Journal of Clinical Oncology 26:592-8, 2008

2. Abrams J, Aisner J, Cirrincione C, et al: Dose-response trial of megestrol acetate in advanced breast cancer: Cancer and leukemia group B phase III study 8741. Journal of Clinical Oncology 17:64-73, 1999

3. Ackland SP, Anton A, Breitbach GP, et al: Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. Journal of Clinical Oncology 19:943-53, 2001

4. Aisner J, Cirrincione C, Perloff M, et al: Combination chemotherapy for metastatic or recurrent carcinoma of the breast - A randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. Journal of Clinical Oncology 13:1443-1452, 1995

5. Alba E, Martin M, Ramos M, et al: Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. Journal of Clinical Oncology 22:2587-93, 2004

6. Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. Journal of Clinical Oncology 26:3950-7, 2008

7. Andersson M, Lindegaard Madsen E, Overgaard M, et al: Doxorubicin versus methotrexate both combined with cyclophosphamide, 5- fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer - A randomised study with more than 10 years follow-up from the Danish breast cancer cooperative group. European Journal of Cancer 35:39-46, 1999

8. Bastholt L, Dalmark M, Gjedde SB, et al: Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative group. Journal of Clinical Oncology 14:1146-1155, 1996

9. Bastit P, Chevallier B, Chevreau C, et al: Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment. Journal of Clinical Oncology 18:3115-3124, 2000

10. Beex L, Rose C, Mouridsen H, et al: Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). European journal of cancer (Oxford, England : 1990) 42:3178-85, 2006

11. Berruti A, Bitossi R, Gorzegno G, et al: Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20:4150-9, 2002

12. Biganzoli L, Cufer T, Bruning P, et al: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. Journal of Clinical Oncology 20:3114-3121, 2002

13. Biron P, Durand M, Roche H, et al: Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone marrow transplantation 41:555-62, 2008

14. Bishop JF, Dewar J, Toner GC, et al: Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology 17:2355-2364, 1999

15. Bishop JF, Smith JG, Jeal PN, et al: The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: a randomised double-blind placebo controlled trial. European Journal of Cancer 29A:814-8, 1993

16. Blackwell KL, Burstein HJ, Storniolo AM, et al: Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28:1124-1130, 2010

17. Blajman C, Balbiani L, Block J, et al: A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 85:1091-1097, 1999

18. Blomqvist C, Elomaa I, Rissanen P, et al: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. Journal of Clinical Oncology 11:467-73, 1993

19. Bonneterre J, Dieras V, Tubiana-Hulin M, et al: Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. British Journal of Cancer 91:1466-1471, 2004

20. Bonneterre J, Roche H, Monnier A, et al: Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. British Journal of Cancer 87:1210-1215, 2002

21. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as firstline therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. Journal of Clinical Oncology 18:3748-57, 2000

22. Bontenbal M, Andersson M, Wildiers J, et al: Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. British journal of cancer 77:2257-63, 1998

23. Brufman G, Colajori E, Ghilezan N, et al: Doubling epirubicin dose intensity (100 mg/m² versus 50 mg/m²) in the FEC regimen significantly increases responses rates. An international randomised phase II study in metastatic breast cancer. Annals of Oncology 8:155-162, 1997

24. Buzdar A, Douma J, Davidson N, et al: Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology 19:3357-3366, 2001

25. Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. Cancer 77:2503-13, 1996

26. Byrne MJ, Gebski V, Forbes J, et al: Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group. Journal of Clinical Oncology 15:3141-8, 1997

27. Calabresi F, Marolla P, Di Lauro L, et al: Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. International Journal of Oncology 4:753-760, 1994

28. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Research and Treatment 112:533-543, 2008

29. Campos SM, Guastalla JP, Subar M, et al: A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clinical Breast Cancer 9:39-44, 2009

30. Cassier PA, Chabaud S, Trillet-Lenoir V, et al: A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Research & Treatment 109:343-50, 2008

31. Castiglione-Gertsch M, Pampallona S, Varini M, et al: Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate? Annals of Oncology 4:735-740, 1993

32. Chan S, Davidson N, Juozaityte E, et al: Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of Oncology 15:1527-1534, 2004

33. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. Journal of Clinical Oncology 17:2341-2354, 1999

34. Chan S, Romieu G, Huober J, et al: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology 27:1753-1760, 2009

35. Cobau CD, Declercq K, Neuberg D, et al: A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer: A study of the Eastern Cooperative Oncology Group (E2185). Cancer 77:483-489, 1996

36. Cocconi G, Bisagni G, Bacchi M, et al: Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: A prospective randomized trial of the Italian oncology group for clinical research. Journal of Clinical Oncology 9:664-669, 1991

37. Cocconi G, Bisagni G, Bella M, et al: Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: A prospective randomized study. American Journal of Clinical Oncology: Cancer Clinical Trials 22:593-600, 1999

38. Cocconi G, Bisagni G, Ceci G, et al: Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: A prospective

randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology 10:984-989, 1992

39. Colleoni M, Orlando L, Sanna G, et al: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Annals of Oncology 17:232-8, 2006

40. Conte PF, Baldini E, Gardin G, et al: Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO). Annals of Oncology 7:487-490, 1996

41. Conte PF, Guarneri V, Bruzzi P, et al: Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101:704-12, 2004

42. Crump M, Gluck S, Tu D, et al: Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. Journal of Clinical Oncology 26:37-43, 2008

43. Del Mastro L, Venturini M, Lionetto R, et al: Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. Journal of Clinical Oncology 19:2213-21, 2001

44. Di Leo A, Gomez HL, Aziz Z, et al: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of Clinical Oncology 26:5544-5552, 2008

45. Dirix LY, Ignacio J, Nag S, et al: Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib. Journal of Clinical Oncology 26:1253-1259, 2008

46. Dogliotti L, Berruti A, Buniva T, et al: Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial. Journal of Clinical Oncology 14:1165-1172, 1996

47. Ejlertsen B, Mouridsen HT, Langkjer ST, et al: Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). Journal of Clinical Oncology 22:2313-20, 2004

48. Ejlertsen B, Pfeiffer P, Pedersen D, et al: Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. European Journal of Cancer Part A: General Topics 29:527-531, 1993

49. Engelsman E, Klijn JC, Rubens RD, et al: "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Cooperative Group Phase III Trial (10808). European Journal of Cancer 27:966-70, 1991

50. Esteban E, Lacave AJ, Fernandez JL, et al: Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Research and Treatment 58:141-150, 1999

51. Feher O, Vodvarka P, Jassem J, et al: First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: A multicenter, randomized, phase III study. Annals of Oncology 16:899-908, 2005

52. Fountzilas G, Athanassiades A, Giannakakis T, et al: A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Annals of Oncology 8:1213-20, 1997

53. Fountzilas G, Dafni U, Dimopoulos MA, et al: A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: A Hellenic Cooperative Oncology Group study. Breast Cancer Research and Treatment 115:87-99, 2009

54. Fountzilas G, Papadimitriou C, Dafni U, et al: Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group. Journal of Clinical Oncology 19:2232-2239, 2001

55. Freue M, Kjaer M, Boni C, et al: Open comparative trial of formestane versus megestrol acetate in postmenopausal patients with advanced breast cancer previously treated with tamoxifen. Breast 9:9-16, 2000

56. Garcia-Giralt E, Ayme Y, Carton M, et al: Second and third line hormonotherapy in advanced post-menopausal breast cancer: A multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen. Breast Cancer Research and Treatment 24:139-145, 1992

57. Gennari A, Amadori D, De Lena M, et al: Lack of benefit of maintenance paclitaxel in firstline chemotherapy in metastatic breast cancer. Journal of Clinical Oncology 24:3912-3918, 2006

58. Gershanovich M, Chaudri HA, Campos D, et al: Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology 9:639-645, 1998

59. Gershanovich M, Garin A, Baltina D, et al: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Research and Treatment 45:251-262, 1997

60. Goss P, Bondarenko IN, Manikhas GN, et al: Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. Journal of Clinical Oncology 25:4961-6, 2007

61. Goss PE, Winer EP, Tannock IF, et al: Randomized phase III trial comparing the new potent and selective third- generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. Journal of Clinical Oncology 17:52-63, 1999

62. Guan ZZ, Li QL, Feng F, et al: Superior efficacy of a cremophor-free albumin-bound paclitaxel compared with solvent-based paclitaxel in chinese patients with metastatic breast cancer. Asia-Pacific Journal of Clinical Oncology 5:165-174, 2009

63. Habeshaw T, Paul J, Jones R, et al: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. Journal of Clinical Oncology 9:295-304, 1991

64. Harper-Wynne C, English J, Meyer L, et al: Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate mitoxantrone (MM) in advanced carcinoma of the breast. British Journal of Cancer 81:316-322, 1999

65. Harris L, Batist G, Belt R, et al: Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94:25-36, 2002

66. Harvey V, Mouridsen H, Semiglazov V, et al: Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. Journal of Clinical Oncology 24:4963-4970, 2006

67. Hausmaninger H, Lehnert M, Steger G, et al: Randomised phase II study of epirubicinvindesine versus mitoxantrone-vindesine in metastatic breast cancer. European Journal of Cancer Part A: General Topics 31:2169-2173, 1995

68. Hayes DF, Van Zyl JA, Hacking A, et al: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. Journal of Clinical Oncology 13:2556-2566, 1995

69. Heidemann E, Steinke B, Hartlapp J, et al: Prognostic subgroups: The key factor for treatment outcome in metastatic breast cancer. Results of three-arm randomized multicenter trial comparing doxorubicin, epirubicin and mitoxantrone each in combination with cyclophosphamide. Onkologie 16:344-353, 1993

70. Heidemann E, Stoeger H, Souchon R, et al: Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Annals of Oncology 13:1717-29, 2002

71. Icli F, Akbulut H, Uner A, et al: Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. British Journal of Cancer 92:639-44, 2005

72. Ingle JN, Foley JF, Mailliard JA, et al: Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer 73:2337-2343, 1994

73. Ingle JN, Twito DI, Schaid DJ, et al: Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67:886-891, 1991

74. Jassem J, Pienkowski T, Pluzanska A, et al: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. Journal of Clinical Oncology 19:1707-15, 2001

75. Jodrell DI, Smith IE, Mansi JL, et al: A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. British Journal of Cancer 63:794-798, 1991

76. Joensuu H, Holli K, Heikkinen M, et al: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. Journal of Clinical Oncology 16:3720-3730, 1998

77. Johnston S, Pippen Jr J, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27:5538-5546, 2009

78. Jonat W, Kaufmann M, Blamey RW, et al: A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre-

and perimenopausal patients with advanced breast cancer. European Journal of Cancer Part A: General Topics 31:137-142, 1995

79. Jones S, Winer E, Vogel C, et al: Randomized comparison of vinorelbine and melphalan in anthracycline- refractory advanced breast cancer. Journal of Clinical Oncology 13:2567-2574, 1995

80. Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology 23:5542-5551, 2005

81. Katsumata N, Watanabe T, Minami H, et al: Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Annals of Oncology 20:1210-5, 2009

82. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 27:5529-5537, 2009

83. Keller AM, Mennel RG, Georgoulias VA, et al: Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. Journal of Clinical Oncology 22:3893-3901, 2004

84. Klijn JGM, Beex LVAM, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. Journal of the National Cancer Institute 92:903-911, 2000

85. Kroger N, Frick M, Gluz O, et al: Randomized trial of single compared with tandem highdose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapysensitive metastatic breast cancer. Journal of Clinical Oncology 24:3919-3926, 2006

86. Langley RE, Carmichael J, Jones AL, et al: Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute Trial AB01. Journal of Clinical Oncology 23:8322-8330, 2005

87. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. Journal of Clinical Oncology 23:5960-5972, 2005

88. Lorusso V, Catino A, Brandi M, et al: Cyclophosphamide, mitoxantrone and fluorouracil versus cyclophosphamide, mitoxantrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial. International Journal of Oncology 4:767-772, 1994

89. Lorusso V, Vici P, Bianco AR, et al: Combination chemotherapy withy CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil, cyclophosphamide) in advanced breast cancer: A multicer randomized study. International Journal of Oncology 2:531-535, 1993

90. Marschner N, Kreienberg R, Souchon R, et al: Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial. Seminars in Oncology 21:10-16, 1994

91. Martin M, Ruiz A, Munoz M, et al: Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes:

final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncology 8:219-225, 2007

92. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. Journal of Clinical Oncology 23:4265-4274, 2005

93. Mavroudis D, Papakotoulas P, Ardavanis A, et al: Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 21:48-54, 2010

94. Meier CR, Illiger HJ, Steder M, et al: Weekly vinorelbine versus docetaxel for metastatic breast cancer after failing anthracycline treatment. Onkologie 31:447-453, 2008

95. Milla-Santos A, Milla L, Rallo L, et al: Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Research and Treatment 65:119-124, 2001

96. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine 357:2666-76, 2007

97. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology 23:792-9, 2005

98. Moulder SL, Holmes FA, Tolcher AW, et al: A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer 116:814-21, 2010

99. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. Journal of Clinical Oncology 21:2101-9, 2003

100. Muss HB, Case LD, Atkins JN, et al: Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 12:1630-8, 1994

101. Muss HB, Case LD, Richards IF, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. New England Journal of Medicine 325:1342-1348, 1991

102. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Journal of Clinical Oncology 18:3758-3767, 2000

103. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. Journal of Clinical Oncology 14:1858-1867, 1996

104. Nabholtz JM, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. Journal of Clinical Oncology 17:1413-1424, 1999

105. Namer M, Soler-Michel P, Turpin F, et al: Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. European Journal of Cancer 37:1132-1140, 2001

106. Nielsen D, Dombernowsky P, Larsen SK, et al: Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemotherapy and Pharmacology 46:459-466, 2000

107. Nielsen D, Dombernowsky P, Skovsgaard T, et al: Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study. Annals of Oncology 1:275-280, 1990

108. Nooij MA, De Haes JCJM, Beex LVAM, et al: Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients: Clinical outcomes and oncologists' preferences. European Journal of Cancer 39:614-621, 2003

109. O'Brien MER, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX[trademark]/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of Oncology 15:440-449, 2004

110. O'Shaughnessy J, Miles D, Vukelia S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. Journal of Clinical Oncology 20:2812-2823, 2002

111. Pacini P, Rinaldini M, Algeri R, et al: FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. European Journal of Cancer 36:966-975, 2000

112. Pandya KJ, Hu P, Osborne CK, et al: Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: An Eastern Cooperative Oncology Group intergroup study (E3185). American Journal of Clinical Oncology: Cancer Clinical Trials 30:113-125, 2007

113. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. Journal of Clinical Oncology 18:724-733, 2000

114. Paridaens R, Heuson JC, Julien JP, et al: Assessment of estrogenic recruitment before chemotherapy in advanced breast cancer: a double-blind randomized study. European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology 11:1723-8, 1993

115. Paridaens R, van Aelst F, Georgoulias V, et al: A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Annals of Oncology 14:433-440, 2003

116. Paridaens RJ, Dirix LY, Beex LV, et al: Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. Journal of Clinical Oncology 26:4883-4890, 2008

117. Parnes HL, Cirrincione C, Aisner J, et al: Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. Journal of Clinical Oncology 21:1819-1824, 2003

118. Pavesi L, Preti P, Da Prada G, et al: Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer. Anticancer Research 15:495-501, 1995

119. Peethambaram PP, Ingle JN, Suman VJ, et al: Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Research and Treatment 54:117-122, 1999

120. Perez EA, Hillman DW, Mailliard JA, et al: Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. Journal of Clinical Oncology 22:2849-55, 2004

121. Pierga JY, Jouve M, Asselain B, et al: Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90). British Journal of Cancer 77:1474-1479, 1998

122. Pyrhonen S, Valavaara R, Modig H, et al: Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'nordic' phase III study. British Journal of Cancer 76:270-277, 1997

123. Rivera E, Mejia JA, Arun BK, et al: Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455-1461, 2008

124. Rixe O, Franco SX, Yardley DA, et al: A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemotherapy & Pharmacology 64:1139-48, 2009

125. Robert N, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 - Overexpressing metastatic breast cancer. Journal of Clinical Oncology 24:2786-2792, 2006

126. Robustelli Della Cuna G, Pannuti F, Martoni A, et al: Aminoglutethimide in advanced breast cancer: Prospective, randomized comparison of two dose levels. Anticancer Research 13:2367-2371, 1993

127. Rose C, Vtoraya O, Pluzanska A, et al: An open randomised trial of second-line endocrine therapy in advanced breast cancer: Comparison of the aromatase inhibitors letrozole and anastrozole. European Journal of Cancer 39:2318-2327, 2003

128. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840. Journal of Clinical Oncology 26:1642-1649, 2008

129. Sjostrom J, Blomqvist C, Mouridsen H, et al: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. European Journal of Cancer 35:1194-1201, 1999

130. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 344:783-792, 2001

131. Sledge GW, Jr., Hu P, Falkson G, et al: Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 18:262-6, 2000

132. Smith RE, Brown AM, Mamounas EP, et al: Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. Journal of Clinical Oncology 17:3403-11, 1999

133. Sparano JA, Makhson AN, Semiglazov VF, et al: Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: Results from a randomized phase III study. Journal of Clinical Oncology 27:4522-4529, 2009

134. Sparano JA, Bernardo P, Stephenson P, et al: Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. Journal of Clinical Oncology 22:4683-90, 2004

135. Stadtmauer EA, O'Neill A, Goldstein LJ, et al: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. New England Journal of Medicine 342:1069-1076, 2000

136. Swain SM, Whaley FS, Gerber MC, et al: Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. Journal of Clinical Oncology 15:1318-1332, 1997

137. Van Toorn DW, Nortier JWR, Rubach M, et al: Randomized phase II study of FEC day 1 + 8 and FEC day 1 in patients with advanced breast cancer. Breast Cancer Research and Treatment 60:57-62, 2000

138. Venturini M, Michelotti A, Del Mastro L, et al: Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. Journal of Clinical Oncology 14:3112-3120, 1996

139. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology 20:719-726, 2002

140. Von Minckwitz G, Du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03-05 study. Journal of Clinical Oncology 27:1999-2006, 2009

141. Winer EP, Berry DA, Woolf S, et al: Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. Journal of Clinical Oncology 22:2061-2068, 2004

142. Wishart GC, Bissett D, Paul J, et al: Quinidine as a resistance modulator of epirubicin in advanced breast cancer - mature results of a placebo-controlled randomized trial. Journal of Clinical Oncology 12:1771-1777, 1994

143. Yardley DA, Burris IHA, Spigel DR, et al: A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer. Clinical Breast Cancer 9:247-252, 2009

144. Zielinski C, Beslija S, Mrsic-Krmpotic Z, et al: Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial. Journal of Clinical Oncology 23:1401-1408, 2005